|
gptkbp:instanceOf
|
antiretroviral therapy
protease inhibitor
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AF04
|
|
gptkbp:bioavailability
|
86%
|
|
gptkbp:brand
|
gptkb:Zerit
|
|
gptkbp:CASNumber
|
3056-17-5
|
|
gptkbp:chemicalFormula
|
C10H12N2O4
|
|
gptkbp:contraindication
|
gptkb:liver_disease
pancreatitis
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discoveredBy
|
gptkb:Jerome_Horwitz
|
|
gptkbp:eliminationHalfLife
|
1-1.6 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
stavudine
|
|
gptkbp:interactsWith
|
gptkb:didanosine
gptkb:zidovudine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reverse transcriptase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
224.21 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
pancreatitis
peripheral neuropathy
lipodystrophy
lactic acidosis
|
|
gptkbp:synonym
|
gptkb:d4T
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:NRTIs
|
|
gptkbp:bfsLayer
|
5
|